261717-23-1
Chemical Structure
MSX3
- CAS No.: 261717-23-1
- Formula:C21H21N4Na2O7P
- Molecular Weight:518.37
IUPAC Name: sodium (E)-3-(8-(3-methoxystyryl)-7-methyl-2,6-dioxo-1-(prop-2-yn-1-yl)-1,2,6,7-tetrahydro-3H-purin-3-yl)propyl phosphate
InChIKey: ZYVZWCILYQDHNU-TTWKNDKESA-L
SMILES: O=C(N1CC#C)N(CCCOP(O[Na])(O[Na])=O)C2=C(N(C)C(/C=C/C3=CC=CC(OC)=C3)=N2)C1=O
Biological Activity: MSX3 is an orally active, selective A2a adenosine receptor antagonist and a prodrug of MSX2 (HY-117184). MSX3 reduces hyperphosphorylation of Tau at specific epitopes in mice without altering total Tau levels, Tau fragments, or Tau aggregation in these animals. MSX3 enhances spatial memory. MSX3 regulates effort-related decision-making behaviors. MSX3 reverses D2 antagonist-induced suppression of lever pressing, increased Chow feed intake, reduced selection of high-barrier arms, and prolonged response latency, and also slightly attenuates effects induced by D1 antagonists. MSX3 can be used in the research of Tauopathies (Alzheimer's disease-related), depression, and Parkinsonism[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
MSX3 | MSX3 is an orally active, selective A2a adenosine receptor antagonist and a prodrug of MSX2 (HY-117184). MSX3 reduces hyperphosphorylation of Tau at specific epitopes in mice without altering total Tau levels, Tau fragments, or Tau aggregation in these animals. MSX3 enhances spatial memory. MSX3 regulates effort-related decision-making behaviors. MSX3 reverses D2 antagonist-induced suppression of lever pressing, increased Chow feed intake, reduced selection of high-barrier arms, and prolonged response latency, and also slightly attenuates effects induced by D1 antagonists. MSX3 can be used in the research of Tauopathies (Alzheimer's disease-related), depression, and Parkinsonism. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Laurent C, et al. A2A adenosine receptor deletion is protective in a mouse model of Tauopathy. Molecular psychiatry. 2016 Jan;21(1):97-107. [Content Brief]
- [2]. Worden LT, et al. The adenosine A2A antagonist MSX-3 reverses the effort-related effects of dopamine blockade: differential interaction with D1 and D2 family antagonists. Psychopharmacology. 2009 Apr;203(3):489-99. [Content Brief]
- [3]. Mott AM, et al. The adenosine A2A antagonist MSX-3 reverses the effects of the dopamine antagonist haloperidol on effort-related decision making in a T-maze cost/benefit procedure. Psychopharmacology. 2009 May;204(1):103-12. [Content Brief]
